SCHEMBL27218734

SCHEMBL27218734

Cc1cc(N)nc(SCCCc2nc(-c3cccc(C(F)(F)F)c3)no2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 2/20 0.46
▸ LMNA P02545 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ HTT P42858 2/20 0.44
▸ TP53 P04637 2/20 0.44
▸ MAPT P10636 4/20 0.42
▸ FFAR1 O14842 2/20 0.42
▸ SIRT2 Q8IXJ6 1/20 0.42
▸ NR1H4 Q96RI1 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31494416 0.86 RAB9A (0.54) LMNASMN1; SMN2NPC1RAB9AHTT
SCHEMBL27218814 0.80 LMNA (0.55) LMNASMN1; SMN2NPC1RAB9AHTT
SCHEMBL27218893 0.80 S1PR1 (0.47) S1PR1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL27218682 0.80 S1PR1 (0.45) S1PR1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL27218664 0.74 TP53 (0.57) S1PR1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL11919088 0.74 NR1H4 (0.57) S1PR1SMN1; SMN2NPC1RAB9ATP53
SCHEMBL31494380 0.74 ALDH1A1 (0.47) LMNASMN1; SMN2NPC1RAB9AHTT
SCHEMBL27218763 0.74 ALDH1A1 (0.47) LMNASMN1; SMN2NPC1RAB9AHTT
SCHEMBL31494430 0.73 SMN1; SMN2 (0.72) LMNASMN1; SMN2NPC1RAB9AHTT
SCHEMBL2245424 0.70 S1PR1 (0.57) S1PR1SMN1; SMN2NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4232448-B1 AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR Halo Therapeutics Ltd (GB) 2025-05-07 — — EP disclosed
EP-3956323-B1 OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 Halo Therapeutics Ltd (GB) 2025-03-05 — — EP disclosed
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor Halo Therapeutics Ltd (GB) 2024-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240158382-A1 Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor FFAR1, FFAR2, FFAR3 S1PR1 56/4885LMNA 3526/4885SMN1; SMN2 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback